Big-data analysis shows not all MS treatments are equal
March 6, 2017A large international study led by Dr Tomas Kalincik of The University of Melbourne together with the global MSBase Consortium has shown that the treatments alemtuzumab (Lemtrada) and natalizumab (Tysabri) can provide better control of relapses than fingolimod (Gilenya) and interferon-beta. The study was published in the prestigious journal Lancet Neurology.
To read more, click on the link below:
Big-data analysis shows not all MS treatments are equal
Article courtesy of MS Research Australia www.msra.org.au